BioPharmX to Host "State of Acne" Symposium on June 1
- Company to present comprehensive results of BPX-01 phase 2b trial
- Expert panel of dermatologists to address unmet need of acne patients and the future paradigm of new treatments
May 11, 2017
MENLO PARK, Calif., May 11, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, will host the State of Acne Symposium, an investor event being held in New York on June 1, 2017 from 8:00 – 10:30 a.m. EDT to review the detailed findings of its phase 2b acne study.
The company recently announced positive topline results of its phase 2b study of BPX-01, a novel topical minocycline gel product for the treatment of moderate-to-severe acne, which demonstrated a statistically significant reduction of non-nodular inflammatory acne lesions. BioPharmX will present the comprehensive data from this study including results for both the primary and secondary endpoints, detailed safety and tolerability data, such as cutaneous effects, and systemic exposure data, as well as patient-reported outcomes.
During the event, members of the BioPharmX management team and experts from the dermatology community will discuss the comprehensive study findings and address why new innovations and treatment therapies are needed for the millions of people affected by acne worldwide.
Speakers scheduled to present at the event include:
- Hilary Baldwin, M.D., SUNY; Medical Director, Acne Treatment & Research Center in New York
- Jim Leyden, M.D., Professor Emeritus of Dermatology, University of Pennsylvania
- Scott Herron, M.D., Medical Director, BioPharmX
- Neal Bhatia, M.D., Therapeutics Clinical Research, San Diego
- Andrew Alexis, M.D., Chairman, Department of Dermatology at Mount Sinai System in New York
- Ted Lain, M.D., Board-certified dermatologist, Austin, Texas
For more information or to register for the event, please contact firstname.lastname@example.org.
A live webcast of the event presentations will be available online on the Investors page of the BioPharmX corporate website at http://www.biopharmx.investorroom.com/events. A replay will also be available for 90 days following the event.
BPX-011 is a hydrophilic (non-oil-based) topical gel with fully solubilized minocycline that can penetrate the skin to deliver the antibiotic to where acne develops in the pilosebaceous unit.
The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting up to 50 million Americans. The U.S. market for prescription acne medications is estimated at $4 billion.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions and strategies, including, but not limited to, statements regarding, the safety and medical effects of BPX-01, the effect BPX-01 may have on the treatment of acne, the timing of reporting and presenting trial results including the safety and tolerability results from the BPX-01 phase 2b trial, commencement and results of future trials involving BPX-01 and the size of such trials, continued and consistent results in future tests of BPX-01 and absence of side effects of future use of BPX-01. These forward-looking statements may be identified by words such as "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
1 Caution: BPX-01 is a new drug limited by U.S. law to investigational use.
SOURCE BioPharmX Corporation
For further information: Nina Brauer, Senior Manager, Marketing & Communications, email@example.com, (650) 889-5030